Lipiodol as a fiducial marker for image-guided radiation therapy for bladder cancer
International Braz J Urol, ISSN: 1677-6119, Vol: 40, Issue: 2, Page: 190-197
2014
- 19Citations
- 5,270Usage
- 35Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations19
- Citation Indexes19
- 19
- CrossRef4
- Usage5,270
- Full Text Views4,920
- 4,920
- Abstract Views350
- 350
- Captures35
- Readers35
- 35
Article Description
Purpose: To evaluate Lipiodol as a liquid, radio-opaque fiducial marker for image- -guided radiation therapy (IGRT) for bladder cancer. Materials and Methods: Between 2011 and 2012, 5 clinical T2a-T3b N0 M0 stage II-III bladder cancer patients were treated with maximal transurethral resection of a bladder tumor (TURBT) and image-guided radiation therapy (IGRT) to 64.8 Gy in 36 fractions ± concurrent weekly cisplatin-based or gemcitabine chemotherapy. Ten to 15mL Lipiodol, using 0.5mL per injection, was injected into bladder submucosa circumferentially around the entire periphery of the tumor bed immediately following maximal TURBT. The authors looked at inter-observer variability regarding the size and location of the tumor bed (CTV) on computed tomography scans with versus without Lipiodol. Results: Median follow-up was 18 months. Lipiodol was visible on every orthogonal two-dimensional kV portal image throughout the entire, 7-week course of IGRT. There was a trend towards improved inter-observer agreement on the CTV with Lipiodol (p = 0.06). In 2 of 5 patients, the tumor bed based upon Lipiodol extended outside a planning target volume that would have been treated with a radiation boost based upon a cystoscopy report and an enhanced computed tomography (CT) scan for staging. There was no toxicity attributable to Lipiodol. Conclusions: Lipiodol constitutes a safe and effective fiducial marker that an urologist can use to demarcate a tumor bed immediately following maximal TURBT. Lipiodol decreases inter-observer variability in the definition of the extent and location of a tumor bed on a treatment planning CT scan for a radiation boost.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84902662965&origin=inward; http://dx.doi.org/10.1590/s1677-5538.ibju.2014.02.08; http://www.ncbi.nlm.nih.gov/pubmed/24856485; http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382014000200190&lng=en&tlng=en; http://www.scielo.br/pdf/ibju/v40n2/1677-5538-ibju-40-2-0190.pdf; http://www.scielo.br/scielo.php?script=sci_abstract&pid=S1677-55382014000200190&lng=en&tlng=en; http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382014000200190; http://www.scielo.br/scielo.php?script=sci_abstract&pid=S1677-55382014000200190; https://dx.doi.org/10.1590/s1677-5538.ibju.2014.02.08; https://www.scielo.br/j/ibju/a/DP4jLwKSwtQC69YC5r3PgTy/?lang=en
FapUNIFESP (SciELO)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know